Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Colitis, Ulcerative 4Inflammatory Bowel Diseases 3Crohn Disease 3Arthritis, Rheumatoid 3Graft vs Host Disease 2Cachexia 2Anorexia 2Recurrence 1Rare Diseases 1Psoriasis 1Pancreatic Neoplasms 1Lymphoma 1Lung Neoplasms 1Kidney Transplantation 1Inflammation 1Hypertension 1Gastrointestinal Diseases 1Fatigue 1Depressive Disorder, Treatment-Resistant 1Depressive Disorder, Major 1Depression 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1Bipolar Disorder 1Arthritis, Psoriatic 1Anemia 1

Interventions

Etanercept 7tofacitinib 6Adalimumab 4Methotrexate 3secukinumab 2sotrastaurin 1sodium luminolate 1purine 1ixekizumab 1fumaric acid 1calcipotriene 1baricitinib 1apremilast 1Vitamin D 1Vaccines 1Sulfasalazine 1Saline Solution 1Mesalamine 1Mercaptopurine 1Infliximab 1Herpes Zoster Vaccine 1Folic Acid 1Fish Oils 1Fatty Acids, Omega-3 1Eicosapentaenoic Acid 1Eating 1Docosahexaenoic Acids 1Cholecalciferol 1Biopsy 1Anti-Infective Agents, Local 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Psoriasis × Infliximab × Clear all
NCT02376478 2015-03-03

On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection

Medical University of Vienna

Completed
222 enrolled

Psoriasis, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡